Literature DB >> 16883165

Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions.

John R Adler1, Iris C Gibbs, Putipun Puataweepong, Steven D Chang.   

Abstract

OBJECTIVE: The restricted radiation tolerance of the anterior visual pathways represents a unique challenge for ablating adjacent lesions with single-session radiosurgery. Although preliminary studies have recently demonstrated that multisession radiosurgery for selected perioptic tumors is both safe and effective, the number of patients in these clinical series was modest and the length of follow-up limited. The current retrospective study is intended to help address these shortcomings.
METHODS: Forty-nine consecutive patients with meningioma (n = 27), pituitary adenoma (n = 19), craniopharyngioma (n = 2), or mixed germ cell tumor (n = 1) situated within 2 mm of a "short segment" of the optic apparatus underwent multisession image-guided radiosurgery at Stanford University Medical Center. Thirty-nine of these patients had previous subtotal surgical resection, and six had previously been treated with conventional fractionated radiotherapy (6). CyberKnife radiosurgery was delivered in two to five sessions to an average tumor volume of 7.7 cm3 and a cumulative average marginal dose of 20.3 Gy. Formal visual testing and clinical examinations were performed before treatment and at follow-up intervals beginning at 6 months.
RESULTS: After a mean visual field follow-up of 49 months (range, 6-96 mo), vision was unchanged postradiosurgery in 38 patients, improved in eight (16%), and worse in three (6%). In each instance, visual deterioration was accompanied by tumor progression that ultimately resulted in patient death. However, one of these patients, who had a multiply recurrent adrenocorticotropic hormone-secreting pituitary adenoma, initially experienced early visual loss without significant tumor progression after both a previous course of radiotherapy and three separate sessions of radiosurgery. After a mean magnetic resonance imaging follow-up period of 46 months, tumor volume was stable or smaller in all other cases. Two patients died of unrelated nonbrain causes.
CONCLUSION: Multisession radiosurgery resulted in high rates of tumor control and preservation of visual function in this group of perioptic tumors. Ninety-four percent of patients retained or improved preradiosurgical vision. This intermediate-term experience reinforces the findings from earlier studies that suggested that multisession radiosurgery can be a safe and effective alternative to either surgery or fractionated radiotherapy for selected lesions immediately adjacent to short segments of the optic apparatus.

Entities:  

Mesh:

Year:  2006        PMID: 16883165     DOI: 10.1227/01.NEU.0000223512.09115.3E

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  48 in total

Review 1.  Role of stereotactic radiosurgery in the management of pituitary adenomas.

Authors:  Frederic Castinetti; Jean Régis; Henry Dufour; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2010-02-23       Impact factor: 43.330

2.  Hypofractionated stereotactic radiosurgery for large-sized skull base meningiomas.

Authors:  Hyuk-Jin Oh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Do Hoon Kwon; Doheui Lee; KyoungJun Yoon
Journal:  J Neurooncol       Date:  2020-07-01       Impact factor: 4.130

3.  Outcomes of stereotactic radiosurgery and hypofractionated stereotactic radiotherapy for refractory Cushing's disease.

Authors:  Alexander D Sherry; Mohamed H Khattab; Mark C Xu; Patrick Kelly; Joshua L Anderson; Guozhen Luo; Andrea L Utz; Lola B Chambless; Anthony J Cmelak; Albert Attia
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

4.  Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: efficacy and safety of an 800 cGy × 3 daily fractions regimen.

Authors:  Che-Chuan Wang; Scott R Floyd; Chin-Hong Chang; Peter C Warnke; Chung-Ching Chio; Ekkehard M Kasper; Anand Mahadevan; Eric T Wong; Clark C Chen
Journal:  J Neurooncol       Date:  2011-08-31       Impact factor: 4.130

Review 5.  Target delineation and optimal radiosurgical dose for pituitary tumors.

Authors:  Giuseppe Minniti; Mattia Falchetto Osti; Maximillian Niyazi
Journal:  Radiat Oncol       Date:  2016-10-11       Impact factor: 3.481

6.  Optimal strategy of gamma knife radiosurgery for craniopharyngiomas.

Authors:  Yun-Sik Dho; Yong Hwy Kim; Jin Wook Kim; Chul-Kee Park; Hyun-Tai Chung; Seung-Ki Kim; Sun Ha Paek; Kyu-Chang Wang; Dong Gyu Kim
Journal:  J Neurooncol       Date:  2018-07-09       Impact factor: 4.130

7.  Clinical outcomes of perioptic tumors treated with hypofractionated stereotactic radiotherapy using CyberKnife® stereotactic radiosurgery.

Authors:  Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Somjai Dangprasert; Chomporn Sitathanee; Rawee Ruangkanchanasetr; Pornpan Yongvithisatid
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

8.  Surgical outcomes using a medial-to-lateral endonasal endoscopic approach to pituitary adenomas invading the cavernous sinus.

Authors:  Graeme F Woodworth; Kunal S Patel; Benjamin Shin; Jan-Karl Burkhardt; Apostolos John Tsiouris; Edward D McCoul; Vijay K Anand; Theodore H Schwartz
Journal:  J Neurosurg       Date:  2014-02-14       Impact factor: 5.115

Review 9.  Applications of radiotherapy and radiosurgery in the management of pediatric Cushing's disease: a review of the literature and our experience.

Authors:  Jay Jagannathan; Adam S Kanter; Claire Olson; Jonathan H Sherman; Edward R Laws; Jason P Sheehan
Journal:  J Neurooncol       Date:  2008-06-21       Impact factor: 4.130

10.  A single-institution restrospective experience of brachytherapy in the treatment of pituitary tumors: transsphenoidal approach combined with (192)Ir-afterloading catheters.

Authors:  A Di Mambro; C Giuliani; F Ammannati; E Mannucci; S Scoccianti; B Detti; I Meattini; P Mennonna; G Forti; M Serio; A Peri
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.